Forte Biosciences Inc
FBRX27.590USD
-1.220-4.23%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
345.53MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Forte Biosciences Inc Unternehmen
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Forte Biosciences Inc Informationen
BörsenkürzelFBRX
Name des UnternehmensForte Biosciences Inc
IPO-datumApr 13, 2017
CEOWagner (Paul A)
Anzahl der mitarbeiter14
WertpapierartOrdinary Share
GeschäftsjahresendeApr 13
Addresse3060 Pegasus Park Drive
StadtDALLAS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl75247
Telefon13106186994
Websitehttps://www.fortebiorx.com/home/default.aspx
BörsenkürzelFBRX
IPO-datumApr 13, 2017
CEOWagner (Paul A)
Führungskräfte von Forte Biosciences Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
83.18K
+1086.00%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
41.60K
+221.00%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
83.18K
+1086.00%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
41.60K
+221.00%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Thu, Jan 22
Aktualisiert: Thu, Jan 22
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Fred Alger Management, LLC
13.06%
Federated Hermes Global Investment Management Corp.
13.05%
Janus Henderson Investors
11.21%
OrbiMed Advisors, LLC
9.56%
Affinity Asset Advisors LLC
6.49%
Andere
46.64%
Aktionäre
Aktionäre
Anteil
Fred Alger Management, LLC
13.06%
Federated Hermes Global Investment Management Corp.
13.05%
Janus Henderson Investors
11.21%
OrbiMed Advisors, LLC
9.56%
Affinity Asset Advisors LLC
6.49%
Andere
46.64%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
46.65%
Hedge Fund
32.83%
Private Equity
9.56%
Investment Advisor
7.50%
Corporation
2.86%
Individual Investor
1.11%
Research Firm
0.12%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
74
10.85M
55.59%
--
2025Q3
75
10.85M
55.60%
+222.21K
2025Q2
78
10.20M
43.87%
+4.95M
2025Q1
72
5.29M
79.85%
+32.05K
2024Q4
73
5.16M
31.17%
+3.22M
2024Q3
65
789.31K
58.51%
-26.11K
2024Q2
72
815.46K
58.79%
-11.24K
2024Q1
101
826.69K
59.45%
-38.71K
2023Q4
113
819.35K
60.39%
+5.27K
2023Q3
130
814.23K
49.33%
+164.66K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Fred Alger Management, LLC
1.64M
13.06%
+17.38K
+1.07%
Sep 30, 2025
Federated Hermes Global Investment Management Corp.
1.64M
13.05%
+156.73K
+10.60%
Sep 30, 2025
Janus Henderson Investors
1.40M
11.21%
+8.99K
+0.64%
Sep 30, 2025
OrbiMed Advisors, LLC
1.20M
9.56%
--
--
Sep 30, 2025
Affinity Asset Advisors LLC
840.00K
6.71%
+840.00K
--
Dec 17, 2025
Tybourne Capital Management (HK) Limited
786.65K
6.28%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
566.74K
4.52%
+79.82K
+16.39%
Sep 30, 2025
Cable Car Capital LLC
500.00K
3.99%
--
--
Sep 30, 2025
Sphera Funds Management Ltd.
474.31K
3.79%
-20.80K
-4.20%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Alger 35 ETF
1.35%
Texas Capital Texas Small Cap Equity Index ETF
0.06%
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Alger Mid Cap 40 ETF
0%
Avantis US Small Cap Equity ETF
0%
Alger 35 ETF
Anteil1.35%
Texas Capital Texas Small Cap Equity Index ETF
Anteil0.06%
iShares Micro-Cap ETF
Anteil0.01%
Dimensional US Core Equity 1 ETF
Anteil0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
Fidelity Nasdaq Composite Index ETF
Anteil0%
Alger Mid Cap 40 ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Datum
Ex-Dividendentag
Art
Verhältnis
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
